Differential propensity for major hemorrhagic events in patients with different types of arterial disease

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Thrombosis and Haemostasis

• Publication date

  2011-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1538-7836.2011.04437.xPMID 21752184
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Coronary atherosclerosis and cardiovascular mortality in hemophilia

  2010cited by this paper
• Patients with coronary, cerebrovascular or peripheral arterial obstructive disease differ in risk for new vascular events and mortality: the SMART study

  2010cited by this paper
• Aspirin to Prevent Cardiovascular Disease: The Association of Aspirin Dose and Clopidogrel With Thrombosis and Bleeding

  2009cited by this paper
• Bleeding with anticoagulation therapy – Who is at risk, and how best to identify such patients

  2009cited by this paper
• Expanding the recognition and assessment of bleeding events associated with antiplatelet therapy in primary care.

  2009cited by this paper
• Prothrombotic gene variation and new vascular events after cerebral ischemia of arterial origin

  2008cited by this paper
• The Genetic Architecture of Intracerebral Hemorrhage

  2008cited by this paper
• Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial.

  2007cited by this paper
• One-year cardiovascular event rates in outpatients with atherothrombosis.

  2007cited by this paper
• High-Dose Atorvastatin after Stroke or Transient Ischemic Attack

  2007cited by this paper
• ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patie

  2007cited by this paper
• ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography

  2006cited by this paper
• ACC/AHA Guidelines for the Management of Patients with Peripheral Arterial Disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Associations for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Intervent

  2006cited by this paper
• High-dose atorvastatin after stroke or transient ischemic attack.

  2006cited by this paper
• Polymorphisms of Platelet Adhesive Receptors: Do They Play a Role in Primary Intracerebral Hemorrhage?

  2003cited by this paper
• Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

  2002cited by this paper
• Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

  2002cited by this paper
• Thrombus Formation on Atherosclerotic Plaques: Pathogenesis and Clinical Consequences

  2001cited by this paper
• Second Manifestations of ARTerial disease (SMART) study: Rationale and design

  1999cited by this paper
• Section Editors: the Genetic Architecture of Intracerebral Hemorrhage

  year unknowncited by this paper

• Inpatient Outcomes for Patients With Peripheral Artery Disease Hospitalized for Acute Myocardial Infarction

  2025cites this paper
• Clinical outcome after bleeding events following coronary stenting in patients with and without comorbid peripheral arterial disease

  2024cites this paper
• Antithrombotic Therapy in High Bleeding Risk, Part II: Noncardiac Percutaneous Interventions.

  2024cites this paper
• Impact of extracardiac vascular disease on outcomes of 1.4 million patients undergoing percutaneous coronary intervention

  2022cites this paper
• Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy.

  2021cites this paper
• Haemorrhagic stroke and major bleeding after intervention with biological aortic valve prosthesis: risk factors and antithrombotic treatment

  2020cites this paper
• Outcomes of acute coronary syndrome patients with concurrent extra-cardiac vascular disease in the era of transradial coronary intervention: A retrospective multicenter cohort study

  2019cites this paper
• Interventions for lower extremity peripheral artery disease

  2018cites this paper
• Prognostic Value of Ankle–Brachial Index in Patients Undergoing Percutaneous Coronary Intervention: In-Hospital and 1-Year Outcomes From the SHINANO Registry

  2017cites this paper
• Prolonged vs Short Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With or Without Peripheral Arterial Disease: A Subgroup Analysis of the PRODIGY Randomized Clinical Trial.

  2016cites this paper
• The pharmacology of novel oral anticoagulants

  2013cites this paper